eligibility_summary
Eligible: adults or children with autoimmune encephalitis (anti-GAD, NMDAR, LGI1, CASPR2, IgLON5, or GFAP), either untreated or with a decision to treat within the last 30 days. Exclude: participation refused by the referring physician or the patient (objection to use of clinical data).
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
NCT07133113 (observational): Evaluates medium-term outcomes of standard regimens in new/early-treated autoimmune encephalitis (NMDAR, LGI1, CASPR2, IgLON5, GFAP, GAD65). Interventions observed (not assigned): • First-line: corticosteroids (glucocorticoids, immunosuppressive/anti-inflammatory via GR-mediated cytokine suppression and lymphocyte apoptosis), IVIG (biologic pooled IgG, FcγR/complement modulation, anti-idiotype neutralization), plasma exchange (procedure, removes circulating autoantibodies/immune complexes). • Second-line/escation: rituximab (anti-CD20 monoclonal antibody, depletes B cells), cyclophosphamide (alkylating chemotherapy, cytotoxic to proliferating B/T cells), tocilizumab (anti–IL-6R monoclonal antibody, blocks IL-6 signaling, reduces plasmablasts/inflammation), dual immunosuppression = rituximab+cyclophosphamide. Targets/pathways: pathogenic autoantibody-driven CNS inflammation, B-cell lineage (CD20+ B cells, plasmablasts), T cells, IL-6 signaling, complement/Fc pathways, and rapid autoantibody removal, antigens: NMDAR, LGI1, CASPR2, IgLON5, GAD65, GFAP.